Clinical Trial Update: BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing afatinib (BIBW 2992) to gemcitabine-cisplatin in first-line non-small cell lung cancer has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2015-01-26